Cardiotoxicity in Canis lupus familiaris (dog) assessed as change in left ventricular contractility at 1.5 to 15 mg/kg, po
|
Canis lupus familiaris
|
None
|
|
Cardiotoxicity in Canis lupus familiaris (dog) assessed as change in ECG at 1.5 to 15 mg/kg, po
|
Canis lupus familiaris
|
None
|
|
Cardiotoxicity in Canis lupus familiaris (dog) assessed as change in heart rate at 1.5 to 15 mg/kg, po
|
Canis lupus familiaris
|
None
|
|
Toxicity in Rattus norvegicus (rat) at 30 mg/kg, po QD for 5 days
|
Rattus norvegicus
|
None
|
|
Reduction in mean arterial blood pressure in po dosed normotensive Canis lupus familiaris (dog)
|
Canis lupus familiaris
|
None
|
|
Antagonist activity at ETA receptor in Rattus norvegicus (rat) assessed as inhibition of ET1-induced pressor response at 10 mg/kg, po administered 3 hr post ET1-induction measured up to 12 hr
|
Rattus norvegicus
|
None
|
|
Antagonist activity at ETA receptor in Rattus norvegicus (rat) assessed as inhibition of ET1-induced pressor response at 0.6 mg/kg, po administered 3 hr post ET1-induction
|
Rattus norvegicus
|
None
|
|
Antagonist activity at ETA receptor in Rattus norvegicus (rat) assessed as inhibition of ET1-induced pressor response at 0.1 mg/kg, po administered 3 hr post ET1-induction
|
Rattus norvegicus
|
None
|
|
Selectivity index, ratio of Ki for Homo sapiens (human) ETB receptor to KI for Homo sapiens (human) ETA receptor
|
Homo sapiens
|
600.0
|
|
Antagonist activity at ETB receptor in Oryctolagus cuniculus (rabbit) pulmonary artery
|
Oryctolagus cuniculus
|
1600.0
nM
|
|
Antagonist activity at ETA receptor in Rattus norvegicus (rat) aorta assessed as inhibition of Kcl-induced contraction
|
Rattus norvegicus
|
11.3
nM
|
|
Antagonist activity at ETA receptor in Homo sapiens (human) umbilical artery
|
Homo sapiens
|
2.5
nM
|
|
Prodrug conversion in Sus scrofa (pig) liver cytosol assessed as (S)-3-(1-(benzo[d][1,3]dioxol-5-yl)-2-(2-methoxy-4-methylphenylsulfonamido)-2-oxoethyl)-1-methyl-1H-indole-6-carboxylic acid formation
|
Sus scrofa
|
None
|
|
Prodrug conversion in Homo sapiens (human) liver cytosol assessed as (S)-3-(1-(benzo[d][1,3]dioxol-5-yl)-2-(2-methoxy-4-methylphenylsulfonamido)-2-oxoethyl)-1-methyl-1H-indole-6-carboxylic acid formation
|
Homo sapiens
|
None
|
|
Prodrug conversion in male Rattus norvegicus (rat) liver cytosol assessed as (S)-3-(1-(benzo[d][1,3]dioxol-5-yl)-2-(2-methoxy-4-methylphenylsulfonamido)-2-oxoethyl)-1-methyl-1H-indole-6-carboxylic acid formation
|
Rattus norvegicus
|
None
|
|
Half life in Rattus norvegicus (rat) liver microsome at 1 uM
|
Rattus norvegicus
|
2.0
hr
|
|
Half life in Canis lupus familiaris (dog) liver microsome at 1 uM
|
Canis lupus familiaris
|
2.0
hr
|
|
Half life in Homo sapiens (human) liver microsome at 1 uM
|
Homo sapiens
|
2.0
hr
|
|
Apparent elimination half life in Rattus norvegicus (rat) assessed as (S)-3-(1-(benzo[d][1,3]dioxol-5-yl)-2-(2-methoxy-4-methylphenylsulfonamido)-2-oxoethyl)-1-methyl-1H-indole-6-carboxylic acid level at 2 mg/kg, po
|
Rattus norvegicus
|
9.0
hr
|
|
Drug absorption in Rattus norvegicus (rat) assessed as (S)-3-(1-(benzo[d][1,3]dioxol-5-yl)-2-(2-methoxy-4-methylphenylsulfonamido)-2-oxoethyl)-1-methyl-1H-indole-6-carboxylic acid level at 2 mg/kg
|
Rattus norvegicus
|
36.0
%
|
|
Tmax in Rattus norvegicus (rat) assessed as (S)-3-(1-(benzo[d][1,3]dioxol-5-yl)-2-(2-methoxy-4-methylphenylsulfonamido)-2-oxoethyl)-1-methyl-1H-indole-6-carboxylic acid level at 2 mg/kg, po
|
Rattus norvegicus
|
4.0
hr
|
|
Cmax in Rattus norvegicus (rat) assessed as (S)-3-(1-(benzo[d][1,3]dioxol-5-yl)-2-(2-methoxy-4-methylphenylsulfonamido)-2-oxoethyl)-1-methyl-1H-indole-6-carboxylic acid level at 2 mg/kg, po
|
Rattus norvegicus
|
0.083
ug.mL-1
|
|
Cmax in Rattus norvegicus (rat) at 2 mg/kg, po
|
Rattus norvegicus
|
0.048
ug.mL-1
|
|
Tmax in Rattus norvegicus (rat) at 2 mg/kg, po
|
Rattus norvegicus
|
0.25
hr
|
|
Prodrug conversion in Rattus norvegicus (rat) assessed as (S)-3-(1-(benzo[d][1,3]dioxol-5-yl)-2-(2-methoxy-4-methylphenylsulfonamido)-2-oxoethyl)-1-methyl-1H-indole-6-carboxylic acid level at 2 mg/kg, po
|
Rattus norvegicus
|
None
|
|
Prodrug conversion in Rattus norvegicus (rat) assessed as (S)-3-(1-(benzo[d][1,3]dioxol-5-yl)-2-(2-methoxy-4-methylphenylsulfonamido)-2-oxoethyl)-1-methyl-1H-indole-6-carboxylic acid level at 2 mg/kg, iv
|
Rattus norvegicus
|
None
|
|
Elimination half life in Rattus norvegicus (rat) at 2 mg/kg, iv
|
Rattus norvegicus
|
1.1
hr
|
|
Volume of distribution in Rattus norvegicus (rat) at 2 mg/kg, iv
|
Rattus norvegicus
|
0.16
L.kg-1
|
|
Displacement of [I125]ET1 from Homo sapiens (human) ETB receptor expressed in CHO cells
|
Homo sapiens
|
1503.0
nM
|
|
Displacement of [I125]ET1 from Homo sapiens (human) ETB receptor expressed in CHO cells
|
Homo sapiens
|
683.0
nM
|
|
Plasma clearance in Rattus norvegicus (rat) at 2 mg/kg, iv
|
Rattus norvegicus
|
1.7
mL.min-1.kg-1
|
|
Displacement of [I125]ET1 from Homo sapiens (human) ETA receptor expressed in CHO cells
|
Homo sapiens
|
2.2
nM
|
|
Displacement of [I125]ET1 from Homo sapiens (human) ETA receptor expressed in CHO cells
|
Homo sapiens
|
2.2
nM
|
|
Selectivity index, ratio of Kb for rabbit ETB receptor to Kb for Homo sapiens (human) ETA receptor
|
Homo sapiens
|
600.0
|
|
Inhibition of endothelin converting enzyme (unknown origin)
|
Homo sapiens
|
765000.0
nM
|
|